NASDAQ:DRMA

Dermata Therapeutics Q3 2026 Earnings Results & Report

Dermata Therapeutics logo
$0.57 -0.03 (-4.75%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.58 +0.01 (+1.56%)
As of 11/17/2026 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dermata Therapeutics met analyst earnings expectations and beat on revenue in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.55 versus the -$0.55 consensus estimate, while revenue of $74.14 thousand topped the $25 thousand estimate by $49.14 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call
7:00 AM ET

Dermata Therapeutics EPS Results

Actual EPS
-$0.55
Consensus EPS
-$0.55
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Dermata Therapeutics Revenue Results

Actual Revenue
$74.14 thousand
Expected Revenue
$25 thousand
Beat/Miss
Beat by +$49.14 thousand
YoY Revenue Growth
N/A

Upcoming Earnings

Dermata Therapeutics' Q4 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules

Dermata Therapeutics Q3 2026 Earnings FAQ

Dermata Therapeutics (NASDAQ:DRMA) reported earnings of -$0.55 per share for Q3 2026, matching the consensus estimate of -$0.55. The report was announced on Tuesday, November 10, 2026.

Dermata Therapeutics reported revenue of $74.14 thousand for Q3 2026, against a consensus estimate of $25 thousand.

Dermata Therapeutics' next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Dermata Therapeutics on the company's earnings history page.

Dermata Therapeutics Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Dermata Therapeutics (DRMA) Set to Announce Quarterly Earnings on Wednesday
See More Dermata Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dermata Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dermata Therapeutics and other key companies, straight to your email.

About Dermata Therapeutics

Dermata Therapeutics (NASDAQ:DRMA) is a clinical-stage biopharmaceutical company focused on developing treatments for skin conditions. The San Diego-based company uses a proprietary technology derived from freshwater sponges to develop topical therapies.

Its lead candidate, DMT310, is an investigational topical treatment being developed for acne. Dermata has also developed DMT410, a candidate that combines its sponge-based technology with botulinum toxin for potential use in dermatologic conditions. These candidates are investigational and have not been approved for marketing.

View Dermata Therapeutics Profile